How are CYP1A2 and weight loss related?

CYP1A2 encodes the primary enzyme responsible for caffeine metabolism. Some studies suggest that 'fast metabolizers' (CYP1A2*1F AA genotype) may experience slightly greater fat oxidation and thermogenesis from caffeine, potentially aiding weight loss when combined with exercise. However, the effect is modest and inconsistent. 'Slow metabolizers' (CC genotype) clear caffeine slowly, which can lead to elevated blood pressure, anxiety, and sleep disruption – factors that may hinder weight loss. The evidence is based on small intervention trials and observational data; no major health organization recommends genotype-guided caffeine dosing for weight management. A CYP1A2 test can offer personalized insight, but lifestyle factors (calorie deficit, physical activity, sleep) remain far more decisive. Caffeine is not a weight loss drug, and high intake carries risks. Therefore, the link between CYP1A2 and weight loss is plausible but weak and not clinically actionable.